Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance

24 May 2008

Abstract excerpt

The Wilms tumor antigen, WT1, is associated with several human cancers, including leukemia. We evaluated WT1 as an immunotherapeutic target using our proven DNA fusion vaccine design, p.DOM-peptide, encoding a minimal tumor-derived major histocompatibility complex (MHC) class I-binding epitope downstream of a foreign sequence of tetanus toxin. Three p.DOM-peptide vaccines, each encoding a different WT1-derived,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18502835
DOI: 10.1182/blood-2008-02-137695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevancePMID 18502835Read ↗

In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.Semantic proximity Read ↗

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.Semantic proximity Read ↗

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell functionSemantic proximity Read ↗

Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II AllelesSemantic proximity Read ↗

“Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone MarrowSemantic proximity Read ↗

Understanding CD8+ T‐cell responses toward the native and alternate HLA‐A∗02:01‐restricted WT1 epitopeSemantic proximity Read ↗

Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapySemantic proximity Read ↗

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.Semantic proximity Read ↗

Baseline WT1-specific immunity and immune responses to WT1-targeted immunotherapy in pediatric patients with malignant solid tumors at high risk for relapse: results from a biomarker-driven multicenter translational phase II clinical trialSemantic proximity Read ↗

Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.Semantic proximity Read ↗

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemiasSemantic proximity Read ↗

Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.